本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 特此公告。 漱玉平民大药房连锁股份有限公司 关于举行 2022 年度网上业绩说明会的公告 漱玉平民大药房连锁股份有限公司 董 事 会 2023 年 5 月 5 日 漱玉平民大药房连锁股份有限公司《2022 年年度报告》及摘要已于 2023 年 4 月 27 日 在巨潮资讯网（http://www.cninfo.com.cn）上披露。为了便于投资者进一步了解公司 2022 年度经营情况，公司将于 2023 年 5 月 15 日（星期一）15:30-17:00 举行 2022 年度网上业 绩说明会。本次年度业绩说明将通过深圳证券交易所提供的"互动易"平台举行，投资者 可登录"互动易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次年度 业绩说明会。 出席本次业绩说明会的人员有：董事长李文杰先生，董事兼总裁秦光霞女士，董事、 副总裁兼董事会秘书李强先生，财务总监胡钦宏先生，独立董事晏莉女士，保荐代表人朱 彤先生。具体以当天实际参会人员为准。 | 证券代码：301017 ...

证券代码：301017 证券简称：漱玉平民 漱玉平民大药房连锁股份有限公司 投资者关系活动记录表 编号：2023-002 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访  业绩说明会（线上） | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及 | 东北证券 刘宇腾、文将儒 中信证券 陈竹、沈睦钧 兴业证券 | 孙 | | 人员姓名 | 媛媛、王佳慧等投资者共 81 人；华创证券 黄致君、胡婧怡 | 国 | | | 金证券 张玉 天风证券 张文星 国盛证券 张金洋、胡婧怡等投 | | | | 资者共 41 人，共计 122 人。 | | | 时间 | 2023 年 4 月 27 日上午、下午 | | | 地点 | 公司总部会议室（电话会议） | | | 上市公司接待人 | 董事、总裁：秦光霞 | | | 员姓名 | 董事、副总裁、董事会秘书：李强 | | | | 财务总监：胡钦宏 | | | | 公司于 2023年 4月 27日通过线上形式召开投资者电话交流 | ...

Financial Performance - The company's revenue for Q1 2023 reached ¥2,072,482,825.34, representing a 30.56% increase compared to ¥1,587,366,356.60 in the same period last year[4] - Net profit attributable to shareholders was ¥64,553,649.73, up 30.38% from ¥49,513,055.97 year-on-year[4] - The basic and diluted earnings per share increased by 33.33% to ¥0.16 from ¥0.12 in the previous year[11] - In Q1 2023, the company achieved operating revenue of CNY 2,072.48 million, a year-on-year increase of 30.56%[19] - The net profit attributable to shareholders was CNY 64.55 million, reflecting a growth of 30.38% compared to the same period last year[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 60.35 million, up 14.28% year-on-year[19] - Net profit for Q1 2023 was ¥66,526,141.25, representing a 34.5% increase from ¥49,492,167.56 in Q1 2022[31] - Operating profit for the quarter was ¥88,553,856.04, up from ¥74,612,400.04, indicating a growth of 18.5% year-over-year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,059,381,246.23, a 2.50% increase from ¥7,863,166,992.04 at the end of the previous year[5] - As of March 31, 2023, total assets amounted to 8,059,381,246.23 CNY, an increase from 7,863,166,992.04 CNY at the beginning of the year[27] - Total liabilities rose to 5,725,138,993.84 CNY from 5,596,102,022.35 CNY, indicating an increase of about 2.3%[28] - The company reported a total equity of 2,296,415,001.54 CNY, up from 2,231,277,500.21 CNY, reflecting an increase of about 2.9%[28] Cash Flow - The net cash flow from operating activities decreased by 9.91% to ¥56,575,234.08 from ¥62,801,486.78 in the same period last year[4] - The company reported a net cash flow from investing activities of -262,700,492.29 CNY, compared to -33,919,646.89 CNY in the previous year[36] - The total cash inflow from financing activities was 51,664,000.00 CNY, down from 163,000,000.00 CNY year-over-year[36] - The net cash flow from financing activities was -282,889,970.43 CNY, a significant decrease from 36,220,433.04 CNY in the same period last year[36] - The net increase in cash and cash equivalents was -489,015,228.64 CNY, compared to an increase of 65,102,272.93 CNY in the previous year[36] - The ending balance of cash and cash equivalents was 1,021,875,903.46 CNY, down from 391,178,131.80 CNY year-over-year[36] Operational Metrics - The company’s gross profit margin improved, with operating costs rising by 33.49% to ¥1,469,857,968.94 due to an increase in store numbers[11] - The company opened 86 new stores and closed 209 stores during the reporting period[19] - As of the end of March 2023, the company operated a total of 6,041 stores, including 3,620 direct-operated stores and 2,421 franchised stores[19] - The company’s direct-operated store distribution includes 3,268 stores in Shandong province[19] - The company maintains a direct chain marketing model and a steady expansion strategy focused on regional development[19] Investments and Financing - The company issued CNY 800 million of convertible bonds on December 15, 2022, with a total issuance amount of CNY 80 million[20] - The convertible bonds began trading on the Shenzhen Stock Exchange on January 6, 2023[20] - The company plans to acquire 60% of Jinan Pingjia Real Estate Co., Ltd. and 90% of Liaoning Tianshili Pharmacy Chain Co., Ltd. through cash payments, currently in the preliminary planning stage[23] Other Financial Information - The company recorded a government subsidy of ¥4,561,774.44, which is closely related to its normal business operations[6] - The company's inventory increased to 2,061,517,554.47 CNY from 1,793,620,391.13 CNY, reflecting a growth of approximately 14.9%[26] - The company’s short-term borrowings decreased to 989,677,435.26 CNY from 1,209,859,212.57 CNY, a reduction of approximately 18.1%[27] - The company’s accounts receivable decreased to 743,322,909.29 CNY from 769,826,716.85 CNY, a decline of about 3.5%[25] - The company’s long-term investments increased slightly to 142,792,812.68 CNY from 141,630,899.74 CNY, showing a growth of approximately 0.8%[26] - The company implemented a restricted stock incentive plan, granting a total of 4.7 million shares at a price of 8.79 CNY per share to 119 incentive targets[21] - The company reported other income of ¥7,322,989.74, which increased from ¥6,810,205.00 in Q1 2022[29] - Investment income from joint ventures and associates was ¥1,161,912.94, a turnaround from a loss of ¥430,424.47 in the previous year[31] Audit Information - The company did not undergo an audit for the first quarter report[37]

Financial Performance - The company's operating revenue for 2022 was ¥7,822,931,715.52, representing a 47.00% increase compared to ¥5,321,639,204.67 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥229,430,842.20, a significant increase of 99.64% from ¥114,924,330.81 in 2021[22] - The net profit after deducting non-recurring gains and losses was ¥220,035,639.01, up 115.18% from ¥102,254,571.67 in the previous year[22] - The basic earnings per share for 2022 was ¥0.57, a 90.00% increase from ¥0.30 in 2021[22] - The total assets at the end of 2022 reached ¥7,863,166,992.04, marking a 57.18% increase from ¥5,002,769,668.71 at the end of 2021[22] - The net assets attributable to shareholders increased by 18.08% to ¥2,231,277,500.21 from ¥1,889,588,905.46 in 2021[22] - The net cash flow from operating activities was ¥148,443,981.75, a decrease of 37.50% compared to ¥237,526,003.92 in 2021[22] - The weighted average return on equity for 2022 was 11.55%, an increase from 6.71% in 2021[22] Market Expansion and Operations - The company expanded its store network to 5,456 locations by the end of 2022, adding 2,115 new stores during the year, including 318 new direct-operated stores and 450 acquired stores[43] - The company operates in multiple provinces including Shandong, Liaoning, Heilongjiang, Fujian, and Henan, expanding its brand influence and market presence[36] - The company has been focusing on developing its wholesale franchise business since the end of 2019 to adapt to industry trends[39] - The company aims to enhance its online sales channels through a combination of B2C and O2O strategies to meet consumer demand for online pharmaceutical purchases[39] - The company is expanding its market presence in northern China, focusing on urban center stores and utilizing big data for site selection and customer flow analysis[62] Product Development and Sales - The company developed a total of 969 SKUs for its proprietary products, achieving a sales growth of 84% year-on-year, accounting for nearly 13% of total retail sales[54] - The "鹊华" brand of traditional Chinese medicine products saw sales increase by over 100% year-on-year due to innovative product development and marketing strategies[66] - New product lines introduced in 2022 contributed to a 25% increase in sales volume, particularly in the health supplement category[160] Financial Management and Investments - The total investment during the reporting period was CNY 839.47 million, a 30.49% increase compared to CNY 643.34 million in the previous year[97] - The company completed significant equity investments totaling approximately RMB 344.84 million during the reporting period[98] - The company raised a total of RMB 108.99502 million through public offerings and convertible bonds, with RMB 20.39 million utilized by the end of the reporting period[103] - The company has a total of RMB 793.5 million remaining in its fundraising account as of December 31, 2022[106] Corporate Governance and Compliance - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management to enhance the effectiveness of performance assessment systems[135] - The company emphasizes investor relations management through various communication methods, including phone calls, online performance briefings, and on-site research[136] - The company has set up an internal audit department to oversee related transactions, external guarantees, and the implementation of internal control systems, ensuring compliance and protecting shareholder rights[138] - The company maintains independence in assets, personnel, finance, institutions, and business operations from its controlling shareholders and actual controllers[139] Social Responsibility and Community Engagement - The company reported a total donation of approximately 17 million yuan for social welfare activities during the reporting period[196] - The company provided over 11 million yuan worth of masks and medical supplies as part of its social responsibility efforts[196] - In December 2022, the company distributed 320,000 acetaminophen tablets for free to pregnant women in Jinan and 6 million ibuprofen tablets benefiting 628,000 people in Shandong Province[196] - The company has established 127 donation points for the "Hope House" charity project, donating over 40,000 books to children in need[197] Employee Management and Development - The total number of employees at the end of the reporting period was 13,270, with 4,548 in the parent company and 8,722 in major subsidiaries[176] - The company has established a comprehensive training system, including various training programs for new employees, in-service staff, and management, to enhance professional skills and service quality[179] - The company plans to implement an employee stock ownership plan to enhance the alignment of interests between employees and owners, improving governance and competitiveness[178]

Financial Performance - The company's revenue for Q3 2022 reached ¥1,857,735,319.22, representing a 50.32% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥18,474,843.69, a decrease of 19.93% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,756,842.71, down 15.32% from the previous year[5] - The company's basic earnings per share for Q3 2022 was ¥0.05, a decline of 16.67% compared to the same period last year[5] - Year-to-date revenue reached RMB 5,247.41 million, up 41.25% year-on-year, with a net profit of RMB 130.00 million, an increase of 18.16%[24] - Net profit for the current period was ¥125,663,645.74, up from ¥110,615,002.37 in the previous period, indicating a growth of approximately 13.6%[48] - The company reported a total profit of ¥163,967,010.65 for the current period, compared to ¥146,458,657.10 in the previous period, marking an increase of about 12.0%[48] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥6,260,311,061.90, reflecting a 25.14% increase from the end of the previous year[5] - The total assets and owners' equity reached ¥6,260,311,061.90 and ¥2,028,727,340.32 respectively, compared to ¥5,002,769,668.71 and ¥1,914,036,739.95 in the previous period[43] - The company's current liabilities totaled approximately 3.71 billion yuan, up from 2.62 billion yuan at the beginning of the year, reflecting increased borrowing and operational scale[39] - The company's long-term equity investments increased by 63.12% to ¥150,801,444.27 due to acquisitions made during the year[12] - The company's short-term borrowings rose by 85.74% to ¥1,023,063,751.55, driven by increased funding needs[12] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥173,063,111.27, showing a slight decrease of 0.37% year-on-year[5] - Cash flow from operating activities was ¥5,285,774,613.04, compared to ¥4,194,835,030.12 in the prior period, showing an increase of approximately 25.9%[52] - Operating cash inflow totaled $5.31 billion, up from $4.22 billion year-over-year, representing a 25.8% increase[55] - Net cash flow from operating activities was $173.06 million, slightly down from $173.71 million year-over-year[55] - Financing cash inflow totaled $894.20 million, compared to $604.27 million in the previous year, marking a 48% increase[58] Shareholder Information - The company has a total of 12,642 common shareholders at the end of the reporting period[16] - Major shareholder Li Wenjie holds 35.17% of the shares, with 142,560,000 shares pledged[16] - Major shareholder Qin Guangxia holds 18.12% of the shares, with 73,440,000 shares pledged[16] - The company plans to lift restrictions on 130,124,807 shares by July 5, 2024, which may impact liquidity[22] Operational Highlights - The company experienced a significant increase in accounts receivable, which rose by 93.79% to ¥602,073,866.46, attributed to the expansion of its store network[12] - As of September 30, 2022, the company had a total of 4,633 stores, including 3,098 direct-operated stores and 1,535 franchised stores, with 251 new stores opened and 276 acquired during the reporting period[26] - The company added 786 franchised stores in the first three quarters of 2022, indicating a strong focus on franchise business development[28] - The sales proportion of DTP products increased from 15.29% in the same period last year to 20.75%, an increase of 5.46 percentage points, resulting in a greater revenue growth than net profit growth due to the lower gross margin of DTP products[26] Strategic Initiatives - The company is focusing on expanding its market presence and developing new products[24] - The company is exploring strategic partnerships and potential acquisitions to enhance growth[24] - The company received approval from the Shenzhen Stock Exchange for its application to issue convertible bonds, indicating potential for future capital raising[29] Cost and Expenses - Total operating costs amounted to ¥5,087,238,933.19, compared to ¥3,573,097,383.25 in the prior period, reflecting an increase of about 42.4%[44] - Cash paid for purchasing goods and services was $3.91 billion, an increase from $3.14 billion year-over-year[55] - Cash paid to employees rose to $736.81 million, compared to $530.89 million in the previous year, reflecting a 38.7% increase[55]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,389,677,274.17, representing a 36.73% increase compared to CNY 2,479,085,397.97 in the same period last year[26]. - Net profit attributable to shareholders was CNY 111,527,935.22, up 28.26% from CNY 86,952,437.27 year-on-year[26]. - The basic earnings per share increased to CNY 0.28, reflecting a growth of 16.67% compared to CNY 0.24 in the previous year[26]. - Total assets at the end of the reporting period reached CNY 5,784,353,097.64, a 15.62% increase from CNY 5,002,769,668.71 at the end of the previous year[26]. - The company's net assets attributable to shareholders were CNY 1,971,527,020.68, which is a 4.34% increase from CNY 1,889,588,905.46 at the end of the previous year[26]. - The net cash flow from operating activities was CNY 106,361,081.41, showing a 33.57% increase from CNY 79,626,689.68 in the same period last year[26]. Store Expansion and Operations - The company opened 668 new stores in the first half of 2022, bringing the total number of stores to 4,009[43]. - The company has 2,970 direct-operated stores, with 174 newly built and 225 acquired stores during the reporting period[43]. - The company experienced a temporary decline in business growth due to pandemic-related restrictions, but operations quickly normalized post-mid-May 2022[43]. - Daily store efficiency averaged 6,242 yuan, with daily sales per square meter at 57 yuan across all stores[51]. - The company continues to optimize its store locations and enhance the DTP area in hospitals to improve patient access to medications[57]. Market and Industry Insights - The retail pharmacy industry in China saw a market size of CNY 469.6 billion in 2021, with a year-on-year growth of 3.21%[37]. - The chain pharmacy concentration rate reached 57.17% by the end of Q3 2021, an increase of 0.67 percentage points from 2020[38]. - The online and offline business segments grew significantly, with increases of 130.71% and 103.24% respectively in 2021[42]. Revenue Streams and Product Development - The company reported a 186.6% year-on-year increase in wholesale revenue from franchise stores in the first half of 2022, with 1,039 franchise stores signed by the end of the reporting period[53]. - The DTP sales revenue exceeded 570 million yuan, representing a year-on-year growth of 84.13%[54]. - Online business revenue surpassed 360 million yuan in the first half of 2022, with third-party B2C platforms accounting for 39% and third-party O2O platforms for 53% of total transactions[58]. - The company has developed nearly 900 SKUs of private label products, with sales increasing by 70% year-on-year, making up over 11% of total retail sales[59]. Financial Management and Investments - The total investment amount during the reporting period was CNY 201,546,400, representing a 1,048.41% increase compared to CNY 17,550,000 in the same period last year[97]. - The company reported a total of CNY 29,936.61 million in raised funds, with CNY 4,364.42 million utilized during the reporting period[99]. - The marketing network construction project has a total investment commitment of CNY 49,712.66 million, with CNY 3,636.80 million invested during the reporting period, achieving 61.71% of the planned investment progress[104]. - The pharmaceutical chain information service platform project has a total investment commitment of CNY 6,274.48 million, with CNY 727.62 million invested during the reporting period, achieving 91.61% of the planned investment progress[104]. Risk Management and Compliance - The company faces various risks including macroeconomic and market risks, which are detailed in the management discussion section of the report[6]. - The company emphasizes the importance of investor awareness regarding potential investment risks associated with forward-looking statements[5]. - The company is committed to monitoring and adapting to industry policy changes to mitigate operational risks[124]. - The company has maintained a focus on environmental responsibility and has not faced any administrative penalties related to environmental issues during the reporting period[144]. Shareholder and Governance Matters - The number of shareholders was 4,662, with 2,230,807 shares released from restrictions, accounting for 0.55% of the total share capital[170]. - The company approved a cash dividend of CNY 0.73 per 10 shares, totaling CNY 29,589,820.00 distributed to shareholders[177]. - The total share capital of the company is 405,340,000 shares, with 91.11% being restricted shares prior to the recent changes[186]. - The largest shareholder, Li Wenjie, holds 35.17% of the shares, amounting to 142,560,000 shares, with 3,700,000 shares pledged[197]. Employee and Community Engagement - The company has actively donated over 11 million RMB in pandemic relief materials and funds during the first half of 2022, including over 4 million RMB to the Shandong Provincial Disabled Persons Welfare Foundation[145]. - The company has implemented a comprehensive recruitment plan and expanded multi-channel recruitment to attract high-level management and professional pharmaceutical talents[130]. - The company has established a mobile learning platform to enhance employee competency across various positions[130]. - The company actively participated in pandemic prevention efforts, establishing a nucleic acid testing "strike team" with nearly 100 medical professionals[148].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,587,366,356.60, representing a 33.99% increase compared to CNY 1,184,719,395.97 in the same period last year[6] - Net profit attributable to shareholders was CNY 49,513,055.97, up 31.61% from CNY 37,620,141.84 year-on-year[6] - The net profit after deducting non-recurring gains and losses increased by 61.60% to CNY 52,812,577.93 from CNY 32,681,017.38 in the previous year[6] - In Q1 2022, the company achieved revenue of RMB 158.74 million, a year-on-year increase of 33.99%[25] - The net profit attributable to shareholders was RMB 49.51 million, up 31.61% year-on-year, while the net profit excluding non-recurring gains and losses reached RMB 52.81 million, a growth of 61.60%[25] - Total operating revenue for the current period reached ¥1,587,366,356.60, an increase of 34.0% compared to ¥1,184,719,395.97 in the previous period[44] - Net profit for the current period was ¥49,492,167.56, representing a 34.3% increase from ¥36,792,571.21 in the previous period[47] - The company reported a total comprehensive income of ¥49,513,055.97 for the current period, compared to ¥37,620,141.84 in the previous period[51] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,423,578,891.92, an increase of 8.41% from CNY 5,002,769,668.71 at the end of the previous year[6] - As of the end of the first quarter of 2022, total assets reached approximately 5.42 billion yuan, up from 5.00 billion yuan at the beginning of the year[36] - Total liabilities amounted to ¥3,457,049,984.41, an increase from ¥3,088,732,928.76 in the previous period[43] - Total current liabilities rose to approximately 2.94 billion yuan from 2.62 billion yuan at the beginning of the year[39] - Total equity attributable to shareholders of the parent company was ¥1,939,101,961.43, up from ¥1,889,588,905.46 in the previous period[43] Cash Flow - Cash flow from operating activities decreased by 29.81% to CNY 62,801,486.78 from CNY 89,476,310.51 in the same period last year[6] - The net cash flow from operating activities was $62,801,486.78, a decrease of 29.8% compared to $89,476,310.51 in the previous period[55] - Cash inflow from investment activities totaled $126,745,211.23, significantly up from $3,063,272.37 in the prior period[55] - The net cash flow from financing activities was $36,220,433.04, recovering from a negative cash flow of $59,928,655.50 in the previous period[58] - The total cash and cash equivalents at the end of the period reached $391,178,131.80, an increase from $275,441,682.73 at the end of the previous period[58] - The company experienced a net increase in cash and cash equivalents of $65,102,272.93, contrasting with a decrease of $1,871,785.51 in the previous period[58] Operational Highlights - The number of accounts receivable increased by 44.74% to CNY 449,690,316.30, primarily due to an increase in store numbers and corresponding receivables[9] - The company's sales expenses rose by 47.93% to CNY 355,006,042.45, attributed to the increase in store numbers[13] - Financial expenses surged by 121.40% to CNY 13,832,467.08, mainly due to the amortization of lease interest expenses under new leasing standards[13] - The company reported a significant increase in investment income, which rose by 276.44% to CNY 2,150,297.68 from a loss of CNY 1,218,688.70 in the previous year[13] - Prepayments increased by 256.67% to CNY 16,007,495.21, primarily due to an increase in prepaid rent[9] - The DTP business recorded a sales revenue of RMB 263 million, representing a year-on-year increase of 68.58%[27] - The company’s new retail strategy led to over RMB 160 million in revenue from third-party B2C and O2O platforms, a growth of 72.5% year-on-year[27] Expansion and Acquisitions - The company expanded its store count to 3,686 by the end of the reporting period, with 2,897 direct-operated stores and 789 franchised stores[26] - The company signed 40 new franchise agreements in Q1 2022, bringing the total number of franchised stores to 789[28] - The company opened 100 new stores across various regions during the reporting period[26] - The company aims to strengthen its presence in northern China, covering provinces such as Liaoning, Heilongjiang, and Henan[30] - The company established a wholly-owned subsidiary in Harbin, Heilongjiang Province, completing business registration on January 18, 2022[31] - The acquisition of 54 stores from Zibo Renjitang by the company's subsidiary Zibo Shuyu Pharmacy was completed in January 2022, enhancing market share in Zibo, Shandong Province[31] - The company’s subsidiary Dongying Yishengtang acquired all operating assets of Dongying Shuyu, integrating 22 stores to improve market concentration in Dongying City[32] - The company and its subsidiary Tai'an Shuyu jointly purchased operational assets from Pingyin Shennong Pharmacy, completed in March 2022, to strengthen market presence in Pingyin County, Jinan City[32] - The company increased its stake in Harbin Baofeng Pharmacy from 10% to 19% by acquiring an additional 9% equity, completed on March 23, 2022[33] - The company purchased 51% equity in Fujian Huibaixing for no more than 50 million yuan, completing the transaction on March 24, 2022[33] - The company acquired 51% equity in Fujian Juzhilin for no more than 40 million yuan, with the transaction completed on March 25, 2022[33] Employee and Operational Costs - Cash outflow for purchasing goods and services was $1,073,255,204.99, up from $880,015,936.49 in the prior period, reflecting increased operational costs[55] - The company paid $238,491,082.66 to employees, which is an increase from $171,130,910.28 in the prior period, reflecting higher payroll expenses[55]

Group 1: Event Announcement - Shuyupingmin Pharmacy Chain Co., Ltd. will participate in the 2021 Annual Investor Online Reception Day organized by Shandong Securities Regulatory Bureau and Shandong Listed Companies Association [2] - The event will take place on November 16, 2021, from 14:00 to 16:00 [2] Group 2: Communication Details - The online platform for the event is provided by Shenzhen Qianjing Network Co., Ltd., accessible via "Qianjing·Roadshow World" website [2] - Company representatives, including Vice President Li Qiang, CFO Hu Qinhong, and Securities Affairs Representative Qi Yanli, will engage with investors online [2] Group 3: Commitment to Transparency - The company and its board members guarantee the accuracy and completeness of the disclosed information, ensuring no false statements or significant omissions [2]

Financial Performance - The company's revenue for Q3 2021 reached ¥1,235,833,319.92, an increase of 13.57% compared to the same period last year[2]. - Net profit attributable to shareholders decreased by 55.83% to ¥23,072,606.54, while the net profit excluding non-recurring gains and losses fell by 52.20% to ¥19,788,874.58[2][5]. - Basic and diluted earnings per share both dropped by 57.14% to ¥0.06[2][6]. - Total operating revenue for Q3 2021 reached CNY 3,714,918,717.89, an increase of 11.4% compared to CNY 3,336,560,975.81 in the same period last year[27]. - Net profit for Q3 2021 was CNY 110,615,002.37, a decrease of 11.1% from CNY 124,404,105.77 in the previous year[28]. Assets and Liabilities - Total assets increased by 41.10% to ¥4,339,402,536.19, primarily due to the implementation of new leasing standards and expansion of business operations[6]. - The company's total liabilities increased to CNY 2,444,582,538.49, compared to CNY 1,545,243,705.35 in the same period last year, representing a growth of 58.2%[26]. - Current liabilities rose to CNY 305,006,323.61, up from CNY 108,106,323.61 at the end of 2020[24]. - The total amount of accounts payable increased to CNY 801,675,742.87 from CNY 592,302,832.33, reflecting a rise of 35.4%[25]. Cash Flow - Cash flow from operating activities showed a slight decrease of 0.19% to ¥173,708,387.88[2]. - The net cash flow from operating activities for Q3 2021 was CNY 173,708,387.88, slightly down from CNY 174,040,434.87 in Q3 2020, indicating a decrease of 0.19%[31]. - The total cash outflow from investing activities was CNY 351,213,735.97, compared to CNY 180,684,650.07 in the previous year, representing an increase of 94.5%[31]. - The net cash flow from financing activities increased significantly to CNY 277,387,091.51 from a negative CNY 4,458,124.06 in Q3 2020, showing a turnaround in financing strategy[31]. Store Expansion and Workforce - A total of 137 new stores were added during the reporting period, representing a year-on-year increase of 280.56%[14]. - Cumulatively, 413 new stores were opened in the first three quarters of the year, a 344.09% increase compared to the same period last year[14]. - The company increased its workforce by 1,572 employees during the reporting period, a 205.84% increase year-on-year[15]. - Cumulative employee growth for the first three quarters reached 2,362, up 275.52% from the previous year[15]. Income and Expenses - Financial expenses rose significantly by 203.70% to ¥18,147,675.75, mainly due to the amortization of leasing interest expenses[8]. - The company reported a substantial increase in other income by 186.96% to ¥12,896,710.83, driven by tax reductions and other subsidies[8]. - Cash paid for dividends and interest increased by 149.36% to ¥51.01 million, attributed to last year's dividends[9]. Business Operations - The company is expanding its marketing network through self-built and acquired stores, focusing on deepening its presence in Shandong and exploring national expansion[15]. - DTP business sales reached CNY 187 million in the reporting period, representing a year-on-year growth of 35.71%[18]. - Online sales surged to CNY 143 million, a 73.4% increase year-on-year, with O2O sales accounting for 63.3% of total online sales[18]. Investments and Acquisitions - The company established a new pharmaceutical industrial park in Zaozhuang with a registered capital of CNY 50 million[19]. - The company invested CNY 1,050,000 in the bankruptcy reorganization of Huangshan Huizhao Medicine Co., acquiring 100% equity[20]. - The company plans to acquire 100% equity of Qihe Taiyao Enterprise Management Co., Ltd. for up to CNY 288 million[21]. Regulatory and Reporting - The third quarter report has not been audited[36]. - The new lease accounting standards were first implemented in 2021, with retrospective adjustments made to prior comparative data[36].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 2,479,085,397.97, representing a 10.26% increase compared to CNY 2,248,392,875.17 in the same period last year[27] - The net profit attributable to shareholders of the listed company was CNY 86,952,437.27, up 22.80% from CNY 70,806,041.87 year-on-year[27] - The net cash flow from operating activities increased significantly by 278.61%, reaching CNY 110,317,146.78 compared to CNY 29,137,627.14 in the previous year[27] - The total assets of the company at the end of the reporting period were CNY 4,192,611,970.66, a 36.33% increase from CNY 3,075,411,628.55 at the end of the previous year[27] - The net assets attributable to shareholders of the listed company increased by 25.42%, amounting to CNY 1,906,204,411.92 compared to CNY 1,519,885,872.71 at the end of the previous year[27] - The basic earnings per share for the reporting period was CNY 0.24, reflecting a 26.32% increase from CNY 0.19 in the same period last year[27] - The company reported a decrease of 22.78% in net profit after deducting non-recurring gains and losses, totaling CNY 79,626,689.68 compared to CNY 103,122,040.10 in the previous year[27] - The weighted average return on net assets was 5.56%, slightly up from 5.24% in the previous year[27] Business Operations - As of June 30, 2021, the company operated 2,149 direct chain stores across 15 cities in Shandong Province, with 1,730 stores qualifying for medical insurance[37] - The company employs a centralized and regional procurement model to meet the operational needs of its stores[39] - The company has adopted a B2C and O2O combined approach to expand sales channels and enhance service coverage[39] - The company maintains a focus on direct chain operations and steady expansion strategies to optimize market layout in Shandong Province[37] - The company reported no significant changes in its main business during the reporting period[38] - The company has established a significant presence in Shandong province, with a focus on expanding its retail pharmacy network[73] - The company opened 275 new stores in the first half of 2021, with 24 stores added through acquisitions[83] Market Trends - The retail drug market in China saw a total sales of CNY 511.9 billion in 2020, with a year-on-year growth of 10.1%[40] - The retail chain rate in China's pharmaceutical retail industry was 56.49% as of the end of 2020, indicating significant room for growth compared to developed countries[44] - The top 100 pharmaceutical retail enterprises accounted for 35.3% of the national retail market total sales, with a total sales of CNY 180.6 billion in 2020[50] - The pharmaceutical retail market is experiencing a significant increase in demand for home medical devices and health products due to the pandemic[43] Digital Transformation - The company has established a new retail data BI platform to enhance operational efficiency and consumer insights[78] - The company is actively developing new business models, including a live streaming marketing approach to enhance customer engagement[79] - The company has integrated digital and physical channels to enhance customer experience and operational efficiency, including a smart order management system[116] - The company has developed a mobile digital management platform, including a staff APP and a DSS mini-program, to facilitate real-time service and management of members[118] Supply Chain and Logistics - The total tax-inclusive procurement amount reached over 2.18 billion RMB, with a centralized procurement ratio exceeding 92.3%[101] - The logistics centers cover a total area of 35,500 square meters, supporting the distribution of products to 15 cities in Shandong province, with over 2.4 million delivery boxes dispatched in the first half of the year[102] - The company implemented electronic delivery tracking and receipt systems in all stores in Jinan, significantly reducing logistics costs and improving operational efficiency[103] Membership and Customer Engagement - As of June 30, 2021, the company had over 12 million members, with a focus on enhancing member management through a comprehensive CRM system[111] - The company established 436 chronic disease management stores and trained 448 chronic disease specialists, serving over 50,000 members in the first half of 2021[107] - The company has conducted over 5,000 patient education sessions related to chronic disease management in the first half of 2021[110] Financial Management - The financial expenses increased by 120.70% to CNY 11.79 million, primarily due to the implementation of new leasing standards[123] - The company's cash and cash equivalents increased significantly by 1763.43% to CNY 394.58 million, driven by increased cash flow from financing and operating activities[123] - The company reported a significant increase in financing cash flow, which rose by 492.79% to CNY 362.40 million, attributed to the successful fundraising efforts[123] Corporate Governance and Social Responsibility - The company has actively participated in social responsibility initiatives, including donating over 4000 boxes of oranges worth more than 120,000 yuan to support poverty alleviation efforts[162] - The company donated over 1 million yuan in pandemic prevention materials to local authorities during the COVID-19 outbreak[164] - The company has not experienced any administrative penalties related to environmental issues[161] - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[137][138] Risks and Challenges - The company faces risks from intensified market competition and is adopting a "new store + acquisition + franchise" model to expand its market presence[148] - The company has established a dedicated team to monitor and adapt to industry policy changes to mitigate operational risks[147]